Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BMS-188667 + Dexamethasone + Ixazomib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BMS-188667 | Abatacept|BMS 188667|BMS188667|RG2077|RG1046|CTLA4-IGG4M|Orencia | Abatacept (BMS-188667) is a recombinant protein containing the extracellular domain of CTLA-4 fused to immunoglobulin G1, which binds to antigen presenting cells expressing CD80 and CD86 and blocks CD28-mediated activation of T cells, potentially enhancing immune suppression (PMID: 31189043, PMID: 32052309). | ||
Dexamethasone | Adexone | Desametasone | ||
Ixazomib | Ninlaro | MLN9708 | Ninlaro (ixazomib) inhibits proteosome activity, resulting in accumulation of misfolded proteins, inhibition of pathway signaling, and potentially leading to cell death (PMID: 20160034). Ninlaro (ixazomib) in combination with Revlimid (lenalidomide) and dexamethasone is FDA approved for use in patients with multiple myeloma who have received at least one prior therapy (FDA.gov) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03457142 | Phase II | BMS-188667 + Dexamethasone + Ixazomib | Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy | Active, not recruiting | USA | 0 |